Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket: aganirsen | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 22 Parkinson's papers of 6,533 | 0.59 |
| pathways Reactome | 18 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3287
Sealed predictions
- IRS1 in dopamine neurons, braak+0.37 (p 0.334) → +0.71 (p 0.032)receipt 3294
Swarm cases
receipt 3294: IRS1 in dopamine neurons, braak
- power
- full sample +0.52 (p 0.028, n 18), 95% CI +0.07 to +0.79. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.43 (p 0.075, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.39 (p 0.109, n 18). could be the mix.
- skeptic
- leave-one-out range +0.45 to +0.61, sign flips 0; without severely affected donors +0.52 (p 0.028, n 18). robust.
- cell type
- strongest in astrocytes: -0.66 (p 0.0030, n 18) vs +0.52 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IRS1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up IRS1 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.68 p 0.016 (needs p < 5.7e-4)
Receipts
loading the receipts